scispace - formally typeset
Search or ask a question
Author

Serena Venegoni

Bio: Serena Venegoni is an academic researcher from University of Eastern Piedmont. The author has an hindex of 1, co-authored 2 publications receiving 9 citations.

Papers
More filters
Journal ArticleDOI
TL;DR: New dimethylamino truncated squalene ether derivatives containing a different aromatic moiety or a simple alkyl (n-hexylic) group were synthesized as inhibitors of the oxidosqualene cyclase (OSC) and of the sterol biosynthetic pathway.

9 citations

Journal ArticleDOI
TL;DR: New dimethylamino truncated squalene ether derivatives containing a different aromatic moiety (phenyl, naphthyl, and biphenyl) or a simple alkyl group were synthesized as inhibitors of the oxidosqualene cyclase (OSC) and of the sterol biosynthetic pathway as mentioned in this paper.
Abstract: New dimethylamino truncated squalene ether derivatives containing a different aromatic moiety (phenyl, naphthyl, and biphenyl) or a simple alkyl (n-hexylic) group were synthesized as inhibitors of the oxidosqualene cyclase (OSC) and of the sterol biosynthetic pathway. The activity against human OSC was compared with the activity against the OSCs of pathogenic organisms such as Pneumocystis carinii and Trypanosoma cruzi. The phenyl derivative was the most potent inhibitor of T. cruzi OSC.

Cited by
More filters
Journal ArticleDOI
TL;DR: There is an urgent need for better drugs to treat chagasic patients and the state of the art of drug targets against Trypanosoma cruzi is reviewed with emphasis on sterol metabolism, kinetoplast DNA sites, trypanothione reductase, cysteine proteinase, hypoxanthine–guanine phosphoribosyltransferase and glyceraldehyde-3-phosphate dehydrogenase.
Abstract: Background: Strategies for development of anti-parasite chemotherapy involve identification of active principles of plants, investigation of drugs already licensed for other pathologies, or validat...

114 citations

Journal ArticleDOI
TL;DR: The most promising OSC inhibitors from different organisms and their potential for the development of new antiparasitic, antifungal, hypocholesterolemic and anticancer drugs are reviewed.

14 citations

Journal ArticleDOI
TL;DR: The screening identified three derivatives particularly promising for the development of novel anti-Trypanosoma agents and eight derivatives for theDevelopment of novelAnti-Pneumocystis agents.

14 citations

Journal ArticleDOI
TL;DR: The atypical organelles /structures present in the parasite relevant clinical forms, while are absent or considerably different from those present in mammals and biological processes related with them can be considered potential targets to develop drugs with extra effectiveness and fewer secondary effects than the currently used.
Abstract: American Trypanosomiasis, a parasitic infection commonly named Chagas disease, affects millions of people all over Latin American countries. Presently, the World Health Organization (WHO) predicts that the number of international infected individuals extends to 7 to 8 million, assuming that more than 10,000 deaths occur annually. The transmission of the etiologic agent, Trypanosoma cruzi, through people migrating to non-endemic world nations makes it an emergent disease. The best promising targets for trypanocidal drugs may be classified into three main groups: Group I includes the main molecular targets that are considered among specific enzymes involved in the essential processes for parasite survival, principally Cruzipain, the major antigenic parasite cysteine proteinase. Group II involves biological pathways and their key specific enzymes, such as Sterol biosynthesis pathway, among others, specific antioxidant defense mechanisms, and bioenergetics ones. Group III includes the atypical organelles /structures present in the parasite relevant clinical forms, which are absent or considerably different from those present in mammals and biological processes related to them. These can be considered potential targets to develop drugs with extra effectiveness and fewer secondary effects than the currently used therapeutics. An improved distinction between the host and the parasite targets will help fight against this neglected disease.

13 citations

Journal ArticleDOI
TL;DR: In cell cultures of both human keratinocytes and mouse 3T3 fibroblasts, the observed inhibition of cholesterol biosynthesis was selective for oxidosqualene cyclase.
Abstract: Human and murine lanosterol synthases (EC 5.4.99.7) were studied as targets of a series of umbelliferone aminoalkyl derivatives previously tested as inhibitors of oxidosqualene cyclases from other eukaryotes. Tests were carried out on cell cultures of human keratinocytes and mouse 3T3 fibroblasts incubated with radiolabeled acetate, and on homogenates prepared from yeast cells expressing human lanosterol synthase, incubated with radiolabeled oxidosqualene. In cell cultures of both human keratinocytes and mouse 3T3 fibroblasts, the observed inhibition of cholesterol biosynthesis was selective for oxidosqualene cyclase. The most active compounds bear an allylmethylamino chain in position-7 of the coumarin ring. The inhibition was critically dependent on the position and length of the inhibitor side chain, as well as on the type of aminoalkyl group inserted at the end of the same chain. Molecular docking analyses, carried out to clarify details of inhibitors/enzyme interactions, proved useful to explain the ...

13 citations